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ABSTRACT
Multiple genome-wide association studies have linked diacylgly-
cerol kinase h (DGKh) to bipolar disorder (BPD). Moreover, DGKh
expression is increased in tissue from patients with BPD. How
increased levels of this lipid kinase might affect cellular functions
is currently unclear. Here, we overexpressed mouse DGKh
in human embryonic kidney 293 cells to examine substrate
specificity and signaling downstream of endogenous G
protein–coupled receptors (GPCRs). We found that DGKh can
phosphorylate diacylglycerol (DAG) with different acyl side chains
(8:0, 12:0, 18:1). In addition, overexpression of DGKh enhanced
calcium mobilization after stimulating muscarinic receptors with
carbachol and after stimulating purinergic receptors with ATP. This
effect required DGKh catalytic activity, as assessed using a kinase-
dead (G389D) mutant and multiple truncation constructs. DGKh
was localized throughout the cytosol and did not translocate to the
plasma membrane after stimulation with carbachol. Since protein
kinase C (PKC) can be activated by DAG and promotes receptor
desensitization, we also examined functional interactions between
PKC and DGKh. We found that acute activation of PKC with
phorbol 12-myristate 13-acetate shortened carbachol-evoked
calcium responses and occluded the effect of overexpressed
DGKh. Moreover, inhibition of PKC activity with bisindolylmaleimide
I (BIM I) produced the same enhancing effect on carbachol-evoked
calciummobilization as overexpressed DGKh, and overexpression
of DGKh produced no additional effect on calcium mobiliza-
tion in the presence of BIM I. Taken together, our data suggest
that DGKh enhances GPCR signaling by reducing PKC
activation.
Introduction
Diacylglycerol kinases (DGKs) are a large family of enzymes
that catalyze the phosphorylation of the membrane lipid
diacylglycerol (DAG) to phosphatidic acid (van Blitterswijk
and Houssa, 2000; Sakane et al., 2007). DAG and phosphatidic
acid are important second messengers and regulate diverse
proteins and pathways, including protein kinase C (PKC)
(Mellor and Parker, 1998), ion channels (Lucas et al., 2003),
endocannabinoid production (Gregg et al., 2012), and phospho-
inositide synthesis (Jenkins et al., 1994). DGKs are thus well
positioned to regulate diverse intracellular signaling pathways
(Merida et al., 2008).
In recent years, several studies have identified genetic
associations betweenDGKH and bipolar disorder (BPD) (Baum
et al., 2008; Squassina et al., 2009; Takata et al., 2011; Weber
et al., 2011; Yosifova et al., 2011; Zeng et al., 2011). DGKH is
the gene that encodes diacylglycerol kinase h (DGKh). In
addition, Moya and colleagues found that DGKh mRNA was
expressed at higher levels in postmortem tissue samples from
patients with BPD than unaffected controls (Moya et al., 2010).
DGKh is a type 2 DGK with two known splice variants (Klauck
et al., 1996;Murakami et al., 2003) andwas recently implicated
in lung cancer (Nakano et al., 2014). However, how alterations
in DGKh levels might affect cellular functions or contribute to
BPD pathogenesis is currently unknown.
Dysregulation of G protein–coupled receptor (GPCR) activity
is involved in the pathology of many psychiatric disorders,
including BPD (Catapano and Manji, 2007). Indeed, tissues
from BPD patients exhibit changes in GPCR (Pantazopoulos
et al., 2004) and G protein subunit expression (Young et al.,
1993; Rao et al., 2009), enhanced receptor–G protein coupling
(Friedman andWang, 1996), and decreased expression of GPCR
kinase 3 (GRK3) (Rao et al., 2009). Furthermore, therapeutic
concentrations of lithium and valproate, common treatments of
BPD, inhibit G protein activation after GPCR stimulation in cell
membranes (Avissar et al., 1988) and platelets from bipolar
patients (Hahn et al., 2005).
Given that DGKh is expressed at higher levels in BPD
patients and has the potential to affect GPCR signaling, we
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sought to determine if overexpression of DGKh affected GPCR
signaling in human embryonic kidney (HEK) 293 cells, a model
cell line with well characterized GPCR signaling cascades (Luo
et al., 2008). Here, we found that overexpression of DGKh
dramatically increased the duration of calcium responses after
stimulating endogenous Gaq-coupled GPCRs. The effect of
DGKh overexpression was dependent on DGKh catalytic
activity and was blocked by inhibition of PKC. Taken together,
our data suggest that DGKh enhances GPCR signaling by
attenuating PKC activity, possibly by attenuating PKC-
dependent receptor desensitization.
Materials and Methods
Carbamoylcholine chloride (carbachol), D-sorbitol, n-butanol,
EDTA, phenylmethanesulfonyl fluoride, sodium fluoride, DL-dithiothreitol
(DTT), sodium deoxycholate, ATP, HEPES sodium salt, glycerol,
sodium pyrophosphate, Dulbecco’s phosphate-buffered saline (PBS),
fatty acid–free bovine serum albumin (BSA), poly-D-lysine, bromophe-
nol blue, and phorbol 12-myristate 13-acetate (PMA) were purchased
from Sigma-Aldrich (St. Louis, MO). Concentrated hydrochloric acid,
Tris hydrochloride (Tris-HCl), sodium chloride (NaCl), magnesium
chloride hexahydrate (MgCl2), SDS, Triton X-100, Tween 20, and
D-glucose were purchased from Fisher Scientific (Waltham, MA).
Bisindolylmaleimide I (BIM I) was purchased from Cayman Chemical
(Ann Arbor, MI). Gö6976 (5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-
indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propanenitrile) was purchased
from Tocris Bioscience (Bristol, UK). BisNonidet P40 substitute (NP40)
was purchased from USB Corporation (Cleveland, OH). g-32P–labeled
ATP (6000 Ci/mmol, 150 mCi/ml) was purchased from PerkinElmer
(Waltham, MA).
Molecular Biology. A full-length clone of mouse DGKh isoform 1
was generated by polymerase chain reaction (PCR) amplification
using cDNA from C57BL/6 mouse neurons as a template (bases
1–3471 from GenBank accession #NM_001081336.1) (Murakami
et al., 2003). The initial clone was found to be unstable due to high
GC content at the 59 end of the DGKh coding sequence. To remedy this
problem, the first 69 bases of the DGKh coding sequence were
modified to decrease GC content while preserving the wild-type (WT)
DGKh amino acid sequence (native sequence: ATG GCC GGG GCC
GGC AGC CAG CAC CAC CCT CAG GGC GTC GCG GGA GGA GCG
GTC GCT GGG GCC AGC GCG; modified sequence: ATG GCA GGA
GCA GGA AGT CAG CAT CAT CCT CAG GGA GTT GCA GGA GGA
GCA GTT GCA GGA GCA ACT GCA). The resulting construct was
stable and was used to generate all subsequent constructs. DGKh
truncation constructs were generated by PCR amplification. The
G389D point mutant was generated by traditional PCR-based
mutagenesis. Full-length DGKh and all DGKh constructs were
inserted into the multiple cloning site of pcDNA 3.1(1) downstream
of monomeric red fluorescent protein (RFP) lacking a stop codon to
create fusion constructs with N-terminal RFP tags. A DGKh-646D
fusion construct with an N-terminal Venus tag was generated in the
same fashion. All constructs contained a Kozak consensus sequence
and were sequence verified.
Cell Culture. HEK293 cells were grown in Dulbecco’s modified
Eagle’s medium (Gibco, Grand Island, NY) containing 10% fetal
bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin at
37°C and 5%CO2. Cells were plated on polylysine-coated glass-bottom
dishes (MatTek, Ashland, MA) for calcium imaging, polylysine-coated
glass coverslips (Brain Research Laboratories, Waban, MA) for
immunostaining, and polylysine-coated six-well plates (Corning,
Corning, NY) for all other experiments. Twenty-four hours after
plating, cells were transfected with Lipofectamine/Plus (Invitrogen,
Carlsbad, CA) in serum-free Dulbecco’s modified Eagle’s medium
according to the manufacturer’s instructions. Each plate/well was
transfected with 500 ng of each DNA construct, and the total amount
of DNA per transfection was normalized to 1 mg with empty vector.
After 4 hours, the transfection medium was replaced with fresh
growth medium. All experiments were performed 24 hours after
transfection.
Calcium Imaging. Calcium imaging was performed as described
previously (Rittiner et al., 2012). Briefly, HEK293 cells expressing
various DGKh constructs and controls were washed twice in Hanks’
balanced salt solution assay buffer (Invitrogen; 140 mg/l CaCl2, 100
mg/l MgCl2-6H2O, 100 mg/l MgSO4-7H2O, 400 mg/l KCl, 60 mg/l
KH2PO4, 350 mg/l NaHCO3, 8 g/l NaCl, 48 mg/l Na2HPO4, 1 g/l
D-glucose, supplemented with 2.4 g/l HEPES, 2 g/l D-glucose, and 0.1%
fatty acid–free BSA, pH 7.3) and loaded with 2 mM Fura-2 AM
(Invitrogen) in 0.02% Pluronic F-127 (Invitrogen) in assay buffer for
1 hour at room temperature. For experiments lacking extracellular
calcium, identical assay buffer lacking CaCl2 was used throughout the
procedure. Cells were then washed three times in assay buffer,
incubated at room temperature for 30 minutes, and imaged on an
Eclipse Ti microscope (Nikon, Tokyo, Japan) at room temperature. A
DG-4 light source (Sutter, Novato, CA), CFI Plan Fluor 20 objective
(Nikon), Clara DR-328G-C01-SIL CCD camera (Andor, Belfast, UK)
and NIS Elements imaging software (Nikon) were used to image
calcium responses. All experiments used 500-millisecond excitation at
340 nm and 250-millisecond excitation at 380 nm. Fura-2 emission
was measured at 510 nm.
Fresh assay buffer was added prior to each experiment. After 40
seconds of baseline imaging, the assay buffer was aspirated and
agonist solution was added. All solutions were aspirated and pipetted
manually. Aspiration or addition of buffer alone did not cause calcium
responses (data not shown, see Fig. 6B, PMA-only trace for equivalent
experiment). For PKC inhibition experiments, inhibitor was added in
assay buffer 30 minutes prior to imaging and was present in all wash
and agonist solutions. Only cells that expressed visible RFP
fluorescence, had low baseline Fura-2 ratios (,0.6), and responded
to agonist stimulation (Fura-2 ratio . 0.8 at any time after agonist
addition) were analyzed. For experiments using cells transfected with
RFP-DGKh-D645 and Venus-DGKh-646D, only cells expressing both
visible RFP fluorescence and visible Venus fluorescence were
analyzed. Real-time response profiles were generated as described
previously (Rittiner et al., 2012). Area under curve (AUC) and peak
response values were calculated relative to baseline Fura-2 ratios on
a cell-by-cell basis and averaged over all cells in each condition. To
control for day-to-day variation in calcium responses, control cells
expressing RFP alone were tested as part of each experiment. AUC
and peak response values were then normalized such that RFP alone
was set at a value of 1. To create scatter plots comparing expression
and AUC values, RFP-DGKh expression levels were calculated for
each cell by quantifying RFP fluorescence.
Confocal Microscopy. HEK293 cells expressing RFP-DGKh
were washed twice in Hanks’ balanced salt solution assay buffer and
imaged using a CSU-10 spinning disc confocal scanner (Yokogawa,
Tokyo, Japan) mounted on a TE2000 microscope (Nikon). An Argon/
Krypton laser light source, Orca-ER camera (Hamamatsu Photonics,
Hamamatsu, Japan), and SimplePCI imaging software (Hamamatsu)
were used to image RFP-tagged DGKh. After approximately 1 minute
of baseline imaging, assay buffer was replaced with buffer containing
10 mM carbachol or 500 mM sorbitol, and imaging continued for an
additional 15 minutes. Solutions were removed and added by manual
pipetting.
Immunostaining. HEK293 cells expressing RFP were incubated
in PBS alone or 300 nM PMA in PBS for 10 minutes at 37°C, then
fixed in ice-cold 4% paraformaldehyde (Fisher Scientific) for 15
minutes. After incubating in 0.5% Triton X-100 in PBS for 15minutes,
coverslips were blocked for 30 minutes in blocking solution—0.1%
Triton X-100 and 5% normal goat serum (Invitrogen) in PBS—then
incubated with rabbit anti-PKCd primary antibody (Santa Cruz
Biotechnology, Santa Cruz, CA) in blocking solution overnight at 4°C.
Cells were then washed with 10% goat serum in PBS for 30 minutes
and incubated in Alexa Fluor 488–conjugated goat anti-rabbit
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secondary antibody (Invitrogen) and DRAQ5 nuclear dye (Cell
Signaling Technology, Beverly, MA) in blocking solution for 1 hour
at room temperature. Cells were washed three times (5 minutes/
wash) with PBS between each step. Coverslips were mounted onto
microscope slides (Fisher Scientific) with Fluoro-Gel (Electron
Microscopy Sciences, Hatfield, PA) and stored at 4°C. Slides were
imaged at room temperature the following day on an LSM 510
microscope (Zeiss, Oberkochen, Germany), using multiline Argon and
Helium-Neon laser light sources, a 63 objective, and ZEN imaging
software (Zeiss).
In Vitro Kinase Assay. The DGK in vitro kinase assay was
adapted from previous studies (Kanoh et al., 1992; Ohanian and
Heagerty, 1994). HEK293 cells expressing RFP-tagged DGKh (WT or
truncation constructs) or RFP alone were washed twice with ice-cold
PBS and scraped into ice-cold lysis buffer—50mMTris-HCl pH 7.5, 150
mM NaCl, 1 mM EDTA, 1 mM phenylmethanesulfonyl fluoride, 1
Complete Mini protease inhibitor cocktail (Roche, Basel, Switzerland),
1 Phosphatase Inhibitor Cocktail 2 (Sigma-Aldrich)—to preserve any
potential phosphorylation events on protein. Cells were disrupted by
brief sonication on ice, and debris was collected by centrifugation at
10,000g for 10 minutes at 4°C. Clarified lysates were kept on ice.
The final reaction mixture contained 50 mM Tris-HCl pH 7.4,
100 mM NaCl, 20 mM NaF, 10 mM MgCl2, 1 mM DTT, 1 mM EDTA,
1 mM sodium deoxycholate, 0.5 mM DAG (8:0, 12:0, or 18:1), 1 mM
[g-32P]ATP (50mCi/rxn), and lysate; reactionvolumewas50ml. A calculated
amount of 1,2-dioctanoyl-glycerol (8:0 DAG), 1,2-dilauroyl-glycerol (12:
0 DAG), or 1,2-dioleoyl-glycerol (18:1 DAG) in chloroform (Avanti Polar
Lipids, Alabaster, AL) was deposited in a glass tube under a stream of
dry nitrogen gas. The DAG was then resuspended in an appropriate
amount of 5 kinase buffer (250 mM Tris-HCl pH 7.4, 500 mM NaCl,
100 mM NaF, 50 mM MgCl2, 5 mM DTT, 5 mM EDTA) and 10 mM
sodium deoxycholate by brief bath sonication. 15 ml of the DAG
suspension was added to a tube containing 20 ml of water, followed by
5 ml of 10 mM [g-32P]ATP. The reaction was initiated by adding 10 ml
of lysate, incubated for 3 minutes at 30°C, and then stopped by adding
25 ml of 12 N HCl followed by 750 ml of water saturated with n-butanol.
Lipids were extracted from the reaction mixture by adding 500 ml of
n-butanol, mixing thoroughly, and separating by centrifugation at
1000g for 5minutes. The organic phase (450ml) waswashedwith 500ml
of n-butanol–saturated water and separated by centrifugation, with
care taken not to disturb the aqueous phase. Next, 350ml of this organic
phase was washed again in the same fashion. Finally, 250 ml of the
washed organic phase was transferred to a scintillation vial containing
2 ml of ScintiSafe Econo 2 scintillation fluid (Fisher Scientific), mixed
gently, and counted on a Wallac Rackbeta 1209 liquid scintillation
counter (LKB Instruments, Mount Waverley, VIC, Australia).
For experiments comparing different DGKh truncation constructs,
each lysate sample was analyzed by anti-RFP western blotting as
described below, and the band intensity was quantified using ImageJ
image analysis software (NIH, Bethesda, MD). The DGKh activity
data were corrected for differences in expression, and normalized such
that RFP alone was set at a value of 0, and wild-type DGKhwas set at
a value of 1.
Western Blotting. A 15-ml portion of each lysate used in the in vitro
kinase assay was mixed with an appropriate amount of 4 Laemmli
sample buffer—125 mM Tris-HCl, 40% (v/v) glycerol, 2% (v/v) SDS, 10%
(v/v) b-mercaptoethanol (Bio-Rad, Hercules, CA), 0.02% (w/v) bromophe-
nol blue—and separated by SDS-PAGE on a 4% to 15% gradient gel (Bio-
Rad) at 100 V for 1 hour. Proteins were transferred to a polyvinylidine
fluoride membrane (Bio-Rad) at 100 V for 70 minutes on ice and blocked
with 5% nonfat milk (Bio-Rad) in Tris-buffered saline/Tween 20 (TBST;
100 mM Tris-HCl pH 7.5, 165 mM NaCl, 0.1% Tween 20) for 1 hour at
room temperature. Blots were then incubated with rabbit anti-RFP
primary antibody (Invitrogen) in 5% BSA (Sigma-Aldrich) in TBST
overnight at 4°C. The following day, blots were washed three times
(5 minutes/wash) with TBST and incubated with IRDye800-conjugated
donkey anti-rabbit secondary antibody (LI-COR, Lincoln, NE) in 5%
nonfat milk/TBST for 1.5 hours at room temperature. Blots were then
washed three times (5 minutes/wash) with TBST and imaged on an
Odyssey CLx infrared imaging system (LI-COR).
Coimmunoprecipitation. HEK293 cells expressing tagged
DGKh truncation constructs or fluorescent tags alone were washed
twice with ice-cold PBS and scraped into ice-cold glycerol coimmuno-
precipitation (Co-IP) buffer containing 50 mM HEPES pH 7.4, 250
mMNaCl, 2 mMEDTA, 10% (v/v) glycerol, 0.5% (v/v), BisNonidet P40
substitute, 1 protease inhibitor cocktail, and 1 phosphatase
inhibitor cocktail. Cellular debris was removed by centrifugation at
10,000g for 10 minutes at 4°C, and input aliquots of the clarified
lysate were set aside. The remaining lysate was then incubated with
chicken anti–green fluorescent protein (GFP) primary antibody (Aves
Laboratories, Tigard, OR) or normal chicken IgY control (Santa Cruz
Biotechnology) for 3 hours at 4°C with gentle mixing. Agarose beads
coupled to goat anti-chicken IgY (Aves Laboratories) were then added
to each sample and incubated for 1 hour at 4°C. The beads were
washed four times (5 minutes/wash) with ice-cold glycerol Co-IP
buffer, and bound proteins were eluted from the beads by incubation
with 4 Laemmli sample buffer for 15 minutes at 37°C. Input and IP
fractions were then separated by SDS-PAGE, transferred to poly-
vinylidine fluoride membrane, and blotted as described above, using
rabbit anti-RFP primary antibody. After imaging, blots were reprobed
with rabbit anti-GFP primary antibody (Invitrogen) to determine the
specificity of the precipitation. Samples containing RFP alone were
heated for 5 minutes at 94°C before SDS-PAGE; samples containing
RFP-DGKh constructs were not heated, because we found that DGKh
protein and DGKh truncation constructs were undetectable on
Western blots when heated at 94°C.
Results
Mouse DGKh PhosphorylatesMultiple DAG Substrates.
First, we set out to evaluate whether mouse DGKh isoform 1
was catalytically active (Fig. 1A shows domain structure of
isoform 1, henceforth referred to as DGKh or DGKh1). To
accomplish this, we transfected HEK293 cells with RFP-tagged
DGKh or RFP only (control) expression constructs. One day
later, we prepared cell lysates, incubated these lysates with
purified DAG substrates and [g-32P]ATP, then monitored
32P-labeled phosphatidic acid (32P-PA) formation (Fig. 1B).
This in vitro assay was previously used to monitor DGK
activity (Kanoh et al., 1992; Ohanian and Heagerty, 1994). We
found that kinase reactions containing RFP-DGKh produced
significantly more 32P-PA than reactions containing RFP alone
(Fig. 1C) when 500 mM dioctanoyl (8:0), dilauroyl (12:0), or
dioleoyl (18:1) glycerol was used as substrate. Given thatmouse
DGKh could phosphorylate multiple DAG substrates, and that
18:1 DAG was previously used to characterize human DGKh
and other DGK isoforms (Murakami et al., 2003), we elected to
use 18:1 DAG for subsequent experiments. Furthermore, we
found that 500 mM18:1 DAGwas a saturating concentration of
substrate (Fig. 1D), justifying our use of this DAG concentra-
tion for subsequent in vitro kinase reactions.
DGKh Increases Intracellular Calcium Responses
after GPCR Stimulation. Since DGKh is expressed at
higher levels in patients with bipolar disorder (Moya et al.,
2010), we next sought to determine if overexpression of DGKh
affects endogenous GPCR signaling. We focused our research
on HEK293 cells because they endogenously express the M3
muscarinic acetylcholine receptor, a Gaq-coupled GPCR that
mobilizes intracellular calcium following stimulation with
carbachol (Luo et al., 2008). Carbachol causes calcium release
by specifically activating the M3, but not the M1, receptor in
HEK293 cells (Luo et al., 2008). Moreover, M3 receptor
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desensitization and downstream signaling pathways have been
extensively studied in HEK293 cells (Rumenapp et al., 2001;
Luo et al., 2008). After stimulating with 10 mM carbachol, we
found that the calcium mobilization response was enhanced in
HEK293 cells expressing RFP-DGKh compared with RFP
alone (Fig. 1E). Based on quantifying the area under the curve,
the carbachol-evoked calcium response in RFP-DGKh–expressing
cells was 80% greater than in cells expressing RFP alone
(P , 0.001). However, the peak amplitude of carbachol-evoked
calcium responses in cells expressing RFP alone and RFP-
DGKh was identical (Supplemental Fig. 1), indicating that
overexpression of RFP-DGKh increases the duration, but not
the intensity, of carbachol-evoked calcium mobilization.
Indeed, no significant difference in peak amplitudes was
observed in the vast majority of calcium mobilization
conditions explored in this work (Supplemental Fig. 1), and
the few significant differences that were observed were very
small and without consistent direction. Furthermore, the
N-terminal RFP tag did not affect DGKh activity, as untagged
DGKh, hemagglutinin-DGKh, and DGKh-mCherry also
enhanced carbachol-evoked calcium responses (data not
shown; we identified cells with untagged or hemagglutinin-
tagged DGKh by cotransfecting with Venus, a yellow
fluorescent protein).
We next investigated whether DGKh could increase
calcium mobilization downstream of other Gaq-coupled
GPCRs. To accomplish this, we stimulated HEK293 cells
with 10 mM ATP, which elicits intracellular calcium mobili-
zation by activating endogenous P2Y receptors (Rittiner et al.,
2012). We found that HEK293 cells expressing RFP-DGKh
exhibited elevated ATP-evoked calcium responses compared
with cells expressing RFP alone (Fig. 1F). When quantified by
AUC, ATP-evoked calcium responses in RFP-DGKh–expressing
cells were 81% greater than responses in cells expressing RFP
alone (P , 0.01). These data indicate that overexpression of
DGKh can enhance calcium responses downstream of two
different GPCRs. Since calcium mobilization was more pro-
nounced (longer duration) following endogenous M3 receptor
Fig. 1. Mouse DGKh is catalytically active and enhances GPCR signaling. (A) Domain architecture of DGKh. (B) Schematic of the reaction forming
32P-labeled PA from DAG and radiolabeled ATP. (C) Lysates from HEK293 cells expressing (black) RFP alone or (red) RFP-DGKh were incubated with
the indicated DAG substrates, each at 500 mM. (D) 32P-PA production from reactions containing the indicated concentrations of 18:1 DAG, catalyzed by
lysates from HEK293 cells expressing RFP-DGKh. (E and F) Calcium mobilization in HEK293 cells expressing (black) RFP alone or (red) RFP-DGKh
after stimulation with (E) 10 mM carbachol or (F) 10 mMATP. AUCmeasurements extended for 4 minutes from agonist addition. Data in C and D are the
average of two experiments performed in duplicate. Data in E and F are the average of three independent experiments; n = 41–104 cells per condition.
**P , 0.01; ***P , 0.001 when compared with RFP alone (unpaired t test). All data, including calcium traces, are presented as means 6 S.E. C1, PKC
homology domain 1; PH, pleckstrin homology.
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activation, we focused the remainder of our experiments on
DGKh modulation of M3 receptor activation.
DGKh Catalytic Activity Is Required to Enhance
Carbachol-Evoked Calcium Mobilization. DGKh, like all
type 2 DGKs, possesses a split catalytic domain (Sakane et al.,
2007). To determine if DGKh catalytic activity was required to
enhance carbachol-evoked calcium mobilization, we generated
two DGKh deletion constructs, DGKh-D645 and DGKh-646D,
each containing one-half of the catalytic domain (Fig. 2A). We
also generated DGKh-G389D, containing a point mutation that
is predicted to abolish ATP binding based on homology to other
DGK proteins (Yamada et al., 2003). We found that DGKh-
D645, DGKh-646D, and DGKh-G389D were expressed (Sup-
plemental Fig. 2) but were catalytically inactive, as they
generated no more 32P-PA than lysates containing RFP alone
(Fig. 2B). In contrast, lysates from cells coexpressing DGKh-
D645 and DGKh-646D displayed specific activity (catalytic
activity normalized for expression; Supplemental Fig. 2)
approximately 32% of that of wild-type RFP-DGKh (Fig. 2B),
suggesting the two halves directly interact. Indeed, we found
that RFP-DGKh-D645 coimmunoprecipitated with Venus-
DGKh-646D (Fig. 2C). This interaction was specific to DGKh-
D645 and DGKh-646D and did not involve the fluorescent tags
or nonspecific binding to the immunoprecipitation beads, as
evidenced by controls showing no interaction when either
construct was replaced with a fluorescent protein alone or
when the anti-GFP antibody was replaced with an IgY control
(Fig. 2C).
Additionally, none of these catalytically dead constructs
(DGKh-D645, DGKh-646D, or DGKh-G389D) enhanced cal-
cium mobilization after carbachol stimulation (Fig. 2D). Cells
expressing DGKh-646D alone appeared unhealthy and dis-
played a slight reduction in calcium mobilization. In contrast,
coexpression of each half of DGKh (RFP-tagged DGKh-D645
and Venus-tagged DGKh-646D) increased calcium mobiliza-
tion by 62% (based on AUC measurement, Fig. 2D). These
data indicate that DGKh catalytic activity is required to
enhance carbachol-evoked calcium mobilization.
We next analyzed calcium mobilization AUC data on a cell-
by-cell basis, to determine if the expression level of DGKh
correlated with how effectively DGKh enhanced calcium
mobilization responses. Notably, there was no relationship
between the level of DGKh expression and the extent of
calcium mobilization in cells expressing WT DGKh or kinase-
dead DGKh-G389D (Fig. 2E). There was also no significant
difference in the expression level of WT DGKh and DGKh-
G389D across individual cells. Together, these data suggest
that the amount of DGKh required to maximally enhance
carbachol-evoked calcium mobilization is very small.
We also tested the catalytic activity of several DGKh
truncation constructs lacking other structural domains (Fig.
3A), again normalized to their expression in HEK293 cells
(Supplemental Fig. 2). We found that the pleckstrin homology
domain andC-terminal tail negatively regulatedDGKh catalytic
activity, as measured using the in vitro kinase assay (Fig. 3B).
Truncation of either domain increased DGKh specific activity in
an additive fashion, and the construct lacking both domains
(161D961) displayed a specific activity 6-fold higher than WT
DGKh (Fig. 3B). The C1 domains were required for catalytic
activity in this assay, as both constructs lacking C1 domains
were inactive (Fig. 3B). Furthermore, the presence of catalytic
activity among the DGKh truncation constructs correlated with
the ability to enhance carbachol-evoked calcium mobilization
(Fig. 3, B and C). However, this correlation was not quantitative.
The DGKh truncation constructs with greatly increased cata-
lytic activity (compared with WT DGKh) enhanced calcium
mobilization to an equal or only marginally increased extent.
These data suggest that beyond a certain point, increased DGKh
catalytic activity does not result in an increased effect upon
calcium mobilization. Lastly, we tested the long splice isoform
DGKh2, which contains a C-terminal sterile a motif domain
(Fig. 3A), in both the in vitro kinase and calcium mobilization
assays. We found that DGKh2 had decreased catalytic activity
compared with WT DGKh1 (Fig. 3B) as has been reported
previously (Murakami et al., 2003), and produced only a negli-
gible (P 5 0.057 compared with RFP alone) enhancement of
carbachol-evoked calcium mobilization (Fig. 3C). As with WT
DGKh, we observed no correlation between DGKh expression
and calcium mobilization for any of the DGKh truncation
constructs on a cell-by-cell basis (Supplemental Fig. 3).
DGKh Does Not Affect Endoplasmic Reticulum
Calcium Loading. Next, to determine if DGKh enhanced
calcium responses by affecting the loading of intracellular
calcium stores, and not GPCR signaling per se, we treated
RFP-DGKh–expressing cells and RFP-expressing controls with
1 mM thapsigargin in the presence of extracellular calcium.
Thapsigargin is a noncompetitive sarco/endoplasmic reticulum
calcium ATPase inhibitor that causes the release of intracel-
lular calcium store contents into the cytosol (Jackson et al.,
1988). Calcium release was not significantly different between
cells expressing RFP alone and RFP-DGKh (Fig. 4A), in-
dicating that DGKh has no effect on the loading of intracellular
calcium stores.
When intracellular calcium stores become depleted,
calcium-sensing proteins trigger the opening of calcium
channels in the plasma membrane, allowing the entry of
extracellular calcium, a process known as store-operated
calcium entry (Venkatachalam et al., 2002). To determine
if DGKh enhanced calcium mobilization by affecting this
process, we stimulated cells with carbachol in the absence of
extracellular calcium (to abolish calcium entry through any
channels or transporters). In the absence of extracellular
calcium, carbachol-evoked calcium mobilization was reduced,
particularly in the later stages of the response (compare Fig. 4B
with Fig. 1E). However, overexpression of DGKh still enhanced
the calcium response by 77% (based on AUC measurements)
when compared with RFP alone. This effect was nearly identical
to the 80%AUC increase in the presence of extracellular calcium
(Fig. 1E). Thus, these data indicate that DGKh enhances the
carbachol-evoked calcium response via a mechanism that is not
solely dependent upon the modulation of calcium entry.
DGKhDoes Not Translocate after GPCR Stimulation.
HumanDGKh localizes to the cytosol under baseline conditions
and translocates to endosomes after osmotic shock (Murakami
et al., 2003; Matsutomo et al., 2013). However, whether DGKh
translocates to the plasmamembrane or intracellular compart-
ments following GPCR stimulation is unknown. Using live cell
confocal imaging, we found that mouse DGKh is localized
throughout the cytoplasm in unstimulated cells and did not
translocate to the plasma membrane or to any intracellular
compartment after stimulating with 10 mM carbachol at room
temperature (Fig. 5A). This experiment was conducted under
conditions that were identical to those used in the carbachol-
evoked calciummobilization assay, suggesting that the effects of
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DGKh on GPCR signaling require little if any translocation of
DGKh. Furthermore, we were unable to detect translocation
of DGKh when cells were stimulated with 10 or 100 mM car-
bachol at 37°C (data not shown). Our inability to detect DGKh
translocation was not a technical limitation, as our mouse
DGKh construct rapidly translocated to endosomes after
osmotic shock at room temperature (Fig. 5B), as previously
shown using humanDGKh (Murakami et al., 2003; Matsutomo
et al., 2013).
DGKh Enhances GPCR Signaling by Attenuating
PKC Activation. DAG is a canonical activator of conven-
tional and novel isoforms of PKC (Mellor and Parker, 1998).
Additionally, PKC is directly and indirectly involved in the
phosphorylation and subsequent desensitization of GPCRs
(Krasel et al., 2001; Kelly et al., 2008; Feng et al., 2011).
Therefore, we hypothesized that DGKhmight enhance GPCR
signaling by metabolizing DAG and hence reducing PKC
activation. First, we confirmed that acute treatment with 300-
nM PMA could activate PKC in HEK293 cells. PMA is
a phorbol ester that is structurally similar to DAG and
potently activates multiple PKC isoforms (Blumberg, 1988),
For this control experiment, we focused on PKCd because it is
highly expressed in HEK293 cells (Leaney et al., 2001) and it
is a Ca21-insensitive isoform of PKC (Mellor and Parker,
1998). We found that PMA induced a rapid (within 2 minutes)
translocation of PKCd to the plasma membrane (Fig. 6A).
However, 300 nM PMA did not induce translocation of
overexpressed RFP-DGKh to the plasma membrane or any
other cellular compartment during the same time frame (data
not shown). We then measured calcium mobilization after
Fig. 2. DGKh catalytic activity is required to enhance GPCR signaling. (A) Structure of the DGKh constructs used. DGKh-G389D contains a point
mutation in catalytic domain A. All DGKh constructs were N-terminally tagged with RFP unless otherwise noted. (B) Production of 32P-PA in reactions
containing the indicated DGKh constructs, using 500 mM 18:1 DAG as substrate. Data were normalized to DGKh expression, which was assessed by
Western blotting against RFP, then normalized so that RFP alone = 0 and WT DGKh = 1. Data are the average of two experiments performed in
duplicate. (C) Lysates from HEK293 cells expressing RFP-tagged DGKh-D645 and Venus-tagged DGKh-646D or fluorescent protein controls were
immunoprecipitated using an anti-GFP antibody or an IgY control. Input and precipitated fractions were then run on SDS-PAGE and blotted using an
anti-RFP antibody. The blot was later reprobed with an anti-GFP antibody to verify the specificity of the immunoprecipitation. (D) AUC measurements
of calcium mobilization in HEK293 cells expressing the indicated DGKh constructs after stimulation with 10 mM carbachol, normalized such that RFP
alone = 1. AUC data for the RFP and WT DGKh conditions are also presented, in non-normalized form, in Fig. 1E. Data are the average of three to six
independent experiments; n = 58–162 cells per condition, except DGKh-646D, where n = 23. (E) Scatter plot comparing calcium mobilization AUC
measurements to DGKh expression levels in individual HEK293 cells expressing (red) WT DGKh or (gray) DGKh-G389D. Horizontal dashed line
indicates average level of calcium mobilization in HEK293 cells expressing RFP alone. *P , 0.05; ***P , 0.001 when compared with RFP alone. #P ,
0.05; ##P , 0.01 when compared with WT DGKh. Unpaired t tests were used to compare data. All data are presented as means 6 S.E.
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stimulating RFP- and RFP-DGKh–expressing cells with 300
nM PMA followed immediately by 10 mM carbachol. Stimu-
lation with 300 nM PMA profoundly accelerated the return of
carbachol-evoked calcium mobilization to baseline (compare
Fig. 6B with Fig. 1E). Furthermore, the carbachol-evoked
calcium responses were identical in cells expressing RFP
alone and RFP-DGKh when PKC was acutely activated with
300 nM PMA (Fig. 6B). In contrast, stimulation of RFP-
expressing cells with 300 nM PMA alone did not evoke
a calcium response (Fig. 6B). Taken together, these data
indicate that PKC activation blunts GPCR signaling in
HEK293 cells and occludes the effect of DGKh.
We next determined whether pharmacological inhibition of
PKC activity would enhance GPCR signaling, using the cell-
permeable PKC inhibitor bisindolylmaleimide I (Toullec
et al., 1991). We found that carbachol-evoked calcium
mobilization in RFP-expressing HEK293 cells was dramati-
cally enhanced after preincubation with 1 mMBIM I (Fig. 6C).
This effect was nearly identical to that observed after
expression of RFP-DGKh (compare Fig. 6C with Fig. 1E).
Indeed, BIM I pretreatment yielded an 81% increase in
calcium responses (based on AUCmeasurements), essentially
the same as the 80% AUC increase observed after RFP-DGKh
expression (Fig. 1E). Furthermore, carbachol-evoked calcium
responses were indistinguishable in RFP- and RFP-DGKh–
expressing cells after pretreatment with BIM I (Fig. 6C). A
different PKC inhibitor (1 mMGö6976) also enhanced calcium
mobilization to nearly the same extent in RFP-expressing and
RFP-DGKh–expressing cells (Fig. 6D), although the kinetics
were different when compared with BIM I, possibly because
Gö6976 is selective for the Ca21-sensitive PKCa and PKCb
isoforms (Martiny-Baron et al., 1993). Taken together, these
data show that pharmacological inhibition of PKC activity
both mimics the effect of DGKh and prevents overexpressed
DGKh from enhancing calcium mobilization further. The
latter finding suggests that PKC inhibitors and overexpressed
DGKh work via a similar mechanism—by inhibiting PKC
directly (inhibitors) or indirectly (by depleting the PKC acti-
vator DAG). Thus, these data suggest that DGKh potentiates
GPCR signaling via PKC, likely by reducing the levels of
a PKC activator (DAG) and attenuating PKC activity.
Discussion
Collectively, our data suggest a model for how DGKh
enhances GPCR signaling (Fig. 7). Stimulation of Gaq-coupled
GPCRs leads to the activation of phospholipase C and the
hydrolysis of phosphatidylinositol 4,5-bisphosphate into inosi-
tol 1,4,5-trisphosphate and DAG. Inositol 1,4,5-trisphosphate
subsequently induces the release of calcium from endoplasmic
reticulum calcium stores, raising the cytosolic concentration of
Ca21. In cells not overexpressing DGKh (Fig. 7A), DAG
activates PKC, leading to the phosphorylation and desensiti-
zation of the activated GPCR, followed by termination of GPCR
signaling (Tang et al., 1995; Gereau and Heinemann, 1998;
Kelly et al., 2008). However, in cells overexpressing DGKh,
Fig. 3. Catalytic activity and signaling effects
of additional DGKh truncation constructs. (A)
Domain architecture of the indicated DGKh
constructs. All constructs were N-terminally
tagged with RFP. (B) Production of 32P-PA in
reactions with the indicated DGKh constructs,
using 500 mM 18:1 DAG as substrate. Data
were normalized to DGKh expression, which
was assessed by Western blotting against
RFP, then normalized so that RFP alone = 0
and WT DGKh = 1. Data are the average of
two experiments performed in duplicate. (C)
AUCmeasurements of calcium mobilization in
HEK293 cells expressing the indicated DGKh
constructs after stimulation with 10 mM
carbachol, normalized such that RFP alone = 1.
Data are the average of three to six in-
dependent experiments; n = 75–209 cells
per condition. *P , 0.05; **P , 0.01; ***P ,
0.001 when compared with RFP alone. #P ,
0.05; ##P, 0.01; ###P, 0.001 when compared
with WT DGKh. Unpaired t tests were used
to compare data. All data are presented as
means 6 S.E.
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DAG is phosphorylated to PA, leading to a decreased level of
PKC activation (Fig. 7B, red). This causes a decrease in the rate
of GPCR phosphorylation and desensitization, resulting in
enhanced GPCR signaling (as evidenced by elevated intracel-
lular calcium release).
During activation, PKC isoforms translocate to the plasma
membrane (Nishizuka, 1984), and are autophosphorylated at
multiple amino acid residues (Keranen et al., 1995; Newton,
2003). We attempted tomeasure PKC activation directly via: 1)
PKCd immunostaining (Fig. 6A), 2) membrane/cytosol frac-
tionation and PKCd Western blotting (Brown et al., 2005), 3)
anti–phospho-PKCd Western blotting (Sumandea et al., 2008),
4) anti–pan-phospho-PKC Western blotting (Iwabu et al.,
2004), 5) a GFP biosensor based on the C1 domains of PKCg
(Oancea et al., 1998), and 6) a FRET biosensor of PKC activity
(Violin et al., 2003). Unfortunately, we did not observe
endogenous PKC activation with any of these techniques after
stimulating endogenous M3 receptors with carbachol, and were
therefore unable to directly measure the effect of DGKh on
endogenous PKC activity. This did not reflect technical
limitations, as we did observe endogenous PKCd activation
after direct stimulation with PMA (Fig. 6A). Instead, our
inability to directly measure endogenous PKC activity suggests
very little PKC is activated when endogenous receptors are
stimulated, likely due to a low level of DAG release. Indeed, we
observed that only a minimal level of DGKh expression results
in the full enhancing effect on calcium mobilization (Fig. 2E),
and that increased DGKh catalytic activity does not increase
this effect beyond a certain point (Fig. 3C). Both these
observations are entirely consistent with DGKh activity being
constrained by a low level of available DAG substrate. In
further support of this possibility, we did not detect an increase
inDAG levels after activating the endogenousM3 receptor with
carbachol (using a sensitive DAG biosensor, Upward DAG2;
data not shown) (Tewson et al., 2013).
Previous studies that measured PKC activity employed
overexpressed receptors (Iwabu et al., 2004; Brown et al.,
2005). It is well documented that overexpressed receptors
activate signaling pathways at nonphysiologic (excessive)
levels relative to endogenous receptor activation (Dickson
et al., 2013). This is precisely why we used endogenous M3
receptors and a sub-EC50 concentration of carbachol (Luo et al.,
2008) in our signaling experiments to probe potential negative
and positive modulation at physiologic levels of GPCR
activation. Although we were unable to directly measure
changes in endogenous PKC activity when stimulating with
carbachol, modulation of PKC activity clearly mediates the
effect of DGKh on GPCR signaling, as both activation (Fig. 6B)
and inhibition (Fig. 6C) of PKC blocked overexpressed DGKh
from enhancing endogenous M3 receptor activation.
It is well established that PKC activation leads to desensiti-
zation of GPCRs (Tang et al., 1995; Gereau and Heinemann,
1998; Kelly et al., 2008). Based on this literature, we suggest that
overexpression of DGKh enhances GPCR signaling by attenu-
ating PKC-mediated phosphorylation and desensitization of
GPCRs (Fig. 7). Such a mechanism should have a greater effect
on the duration of calcium responses than the intensity,
consistent with our findings (Fig. 1, E and F; Supplemental
Fig. 1). Likewise, cholinergic stimulation of cells expressing
a phosphorylation-deficient M3 receptor resulted in enhanced
calciummobilization when compared with cells expressing wild-
type M3 receptor (Kong et al., 2010), resembling the effect of
Fig. 4. DGKh does not affect intracellular calcium stores. Calcium
mobilization in HEK293 cells expressing (black) RFP alone or (red)
RFP-DGKh after (A) stimulation with 1 mM thapsigargin or (B)
stimulation with 10 mM carbachol in the absence of extracellular calcium.
AUC measurements extended 8 minutes (A) or 4 minutes (B) after
stimulation. Data are the average of two (A) or five (B) independent
experiments; n = 69–190 cells per condition. ***P, 0.001 when compared
with RFP alone (unpaired t test). All data, including calcium traces, are
presented as means 6 S.E.
Fig. 5. DGKh does not translocate within cells after GPCR stimulation.
Confocal images of live HEK293 cells expressing RFP-DGKh after
stimulation with (A) 10 mM carbachol or (B) 500 mM sorbitol for the
indicated times. Cell culture and imaging conditions were identical to
those used in calcium mobilization experiments. (A) Cells from in-
dependent experiments are shown in each row.
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overexpressedDGKh followingM3 receptor activation. However,
it remains possible that another mechanism downstream of
PKC, such as modulation of calcium transporter activity
(Usachev et al., 2002, 2006), is responsible for the increased
duration of calcium responses observed in DGKh-expressing
cells.
Note that M3 receptor internalization (as distinct from
desensitization) is not likely to be involved in DGKh-mediated
modulation of receptor signaling, as internalization of the
M3 receptor is very slow (hours), even during continuous
stimulation with an extremely high concentration of carba-
chol (Thangaraju and Sawyer, 2011). Although PKC directly
Fig. 6. DGKh enhances GPCR signaling via PKC. (A)
PKCd translocation following PMA stimulation. Confo-
cal images of HEK293 cells after treatment with (left)
vehicle or (right) 300 nM PMA for 2 minutes. Cells were
fixed, immunostained with an anti-PKCd antibody
(green), and counterstained with DRAQ5 nuclear dye
(blue). (B) Calcium mobilization in HEK293 cells
expressing (black, blue) RFP alone or (red) RFP-DGKh
after stimulation with (black, red) 300 nMPMA followed
by 10 mM carbachol, or (blue) 300 nM PMA alone. AUC
measurements extended 80 seconds from final agonist
addition. Data are the average of two (PMA alone) or
three (PMA + carbachol) independent experiments; n =
49–83 cells per condition. (C and D) Calcium mobiliza-
tion in HEK293 cells expressing (black, blue) RFP alone
or (red) RFP-DGKh after pretreatment with (blue, red)
1 mMPKC inhibitor (C) BIM I or (D) Gö6976. Cells were
stimulated with 10 mM carbachol, and AUC measure-
ments extended 4 minutes from agonist addition. Data
in C are the average of five independent experiments;
n = 140–198 cells per condition. Data in D are the
average of three independent experiments; n = 85–148
cells per condition. ***P , 0.001 when compared with
RFP in the absence of PKC inhibitor; ##P , 0.01 when
compared with RFP plus Gö6976. Unpaired t tests were
used to compare data. All data, including calcium
traces, are presented as means 6 S.E.
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phosphorylates some GPCRs (Kelly et al., 2008; Feng et al.,
2011), phosphorylation of the M3 receptor in HEK293 cells
could be indirect, through the activation of G protein–coupled
receptor kinases. In HEK293 cells, M3 receptor activity is
regulated by GRKs 2, 3, and 6 (Luo et al., 2008), at least one of
which is activated by PKC (Krasel et al., 2001). Interestingly,
GRK3 is also genetically linked to BPD (Rao et al., 2009),
suggesting that dysregulation of GPCR signaling is important
in the pathology of BPD.
Other DGK isoforms regulate PKC and receptor signaling.
For example, disruption of the gene encoding DGKd leads to
DAG accumulation and enhanced PKC activity and epidermal
growth factor receptor (EGFR) phosphorylation (Crotty et al.,
2006), culminating in a PKC-dependent increase in EGFR
ubiquitination and degradation (Cai et al., 2010). DGKs also
regulate inter-receptor desensitization pathways, as DGKu
attenuates bradykinin-evoked, PKC-mediated phosphoryla-
tion of EGFR, a phosphorylation event that is linked to EGFR
desensitization (van Baal et al., 2012). Interestingly, EGFR is
a receptor tyrosine kinase, indicating that regulation of
receptor signaling by DGKs is not limited to GPCRs. These
studies, when combined with our current study, suggest that
multiple members of the DGK enzyme family can regulate
PKC activity and receptor signaling.
Lastly, our study provides new insights into how alterations
in DGKhmight affect cellular signaling in patients with BPD.
Numerous genome-wide association studies have linked
single nucleotide polymorphisms within DGKH to BPD
(Baum et al., 2008; Squassina et al., 2009; Takata et al.,
2011; Weber et al., 2011; Yosifova et al., 2011; Zeng et al.,
2011), although whether these single nucleotide polymor-
phisms increase, decrease, or have no effect on DGKH
expression is unknown. In one study, DGKH was found to
be expressed at higher levels in postmortem tissues from
patients with BPD than unaffected controls (Moya et al.,
2010), suggesting that DGKh enzymatic activity might also be
elevated. Given that overexpression of DGKh enhanced
GPCR signaling in a model cell line, it is tempting to
speculate that GPCR signaling might be dysregulated in
other cell types when DGKh activity is increased or decreased.
Ultimately, future studies will be needed to delineate pre-
cisely how DGKh activity is altered in BPD patients and how
such alterations affect PKC and GPCR signaling in neurons
and in animal models of BPD.
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